AstraZeneca PLCEigentümerstruktur
| Preis (-) | 52W Hoch | 52W Tief |
| - GBP | - GBP | - GBP |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| - GBP | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 1.550.876.987 | 426 | - |
Eigentümerstruktur
Analyse der Aktionärsstruktur und institutionellen Investoren
Unternehmensdaten
Grundlegende Informationen
Grunddaten
Name AstraZeneca PLC
Mitarbeiter 96.100
Handelsplatz LSE
Ticker Symbol AZN
IPO Datum 1993-05-12
Adresse 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
Webseite https://www.astrazeneca.com
Unternehmensführung
| Rang | Name | Position |
|---|---|---|
| 1 | Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | CEO & Executive Director |
| 2 | Dr. Aradhana Sarin M.D. | CFO & Executive Director |
| 3 | Ms. Pam P. Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board |
| 4 | Mr. Joris Silon | Head of Investor Relations |
| 5 | Mr. Jeffrey Pott J.D. | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board |
| 6 | Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit |
| 7 | Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology R&D |
| 8 | Ms. Iskra Reic | Executive Vice President of International |
| 9 | Mr. David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit |
| 10 | Ms. Ruth March FMEDSCI, O.B.E., Ph.D. | Senior VP of Precision Medicine - R&D Oncology |
Aktionärsverteilung
Aufteilung der Investoren
Größte Investoren
Für dieses Unternehmen liegen derzeit keine Daten zu institutionellen Investoren vor.